LLC-LENAR-08 A PHASE I/II STUDY LENALIDOMIDE-RITUXIMAB IN RELAPSE/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Author(s): ,
Adolfo De La Fuente
Affiliations:
Hematology,MD Anderson CC Madrid Spain,Madrid,Spain
,
Marcos Gonzalez
Affiliations:
Hematology,H. U. Salamanca,Salamanca,Spain
,
Pilar Giraldo
Affiliations:
Hematology,H. U. Miguel Servet,Zaragoza,Spain
,
F de la Cruz
Affiliations:
Hematology,H. U. Virgen del Rocio,Sevilla,Spain
,
Maria Jose Terol
Affiliations:
Hematology,H. U. Clinico de Valencia,Valencia,Spain
,
Jose Antonio Perez Simon
Affiliations:
Hematology,H. U. Virgen del Rocio,Sevilla,Spain
,
G Rodriguez
Affiliations:
Hematology,H. U. Reina Sofia Cordoba,Cordoba,Spain
,
Carlos Montalban
Affiliations:
Hematology,MD Anderson CC Madrid Spain,Madrid,Spain
,
Jose Francisco Toas
Affiliations:
Hematology,Bupa-SLA Madrid,Madrid,Spain
Raquel de Oña
Affiliations:
Hematology,MD Anderson CC Madrid Spain,Madrid,Spain
EHA Learning Center. De La Fuente A. Jun 12, 2015; 100471
Disclosure(s): MD Anderson CC Madrid Spain
Hematology
Dr. Adolfo De La Fuente
Dr. Adolfo De La Fuente

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: P217

Type: Poster Presentation

Presentation during EHA20: From 12.06.2015 17:15 to 12.06.2015 18:45

Location: Poster area (Hall C)

Background

Phase II studies showed  lenalidomide monotherapy is active in relapsed and refractory CLL. A synergistic activity between rituximab and lenalidomide against CLL has been suggested and a previous study has evaluated the combination of lenalidomide and rituximab in this population with encouraging results (J Clin Oncol, 2012,31: 584),  but the optimal dose and schedule for this combination remains unknown.



Aims

The endpoint in phase I of this study is to define the optimum dose of lenalidomide in combination with rituximab in R/R CLL patients. The endpoint in  phase II is to evaluate effectiveness and toxic profile of the resulted schedule.



Methods

We carried out a multicenter phase I/II study on R/R CLL patients, in the dose finding phase we started with a continuous lenalidomide daily dose of 2,5mg and rituximab (375mg/m2 cycle 1 and 500mg/m2 cycles 2-6/28 days) with cohorts of 3 patients (if no DLT move to a higher dose; if one DLT occurred in the cohort expand 3 more patients). In the second phase we evaluated efficacy (NCI WGC criteria), toxic profile (CTCAE v3.0 scale) OS and TTP with Kaplan Meier. Study registered in ClinicalTrials.gov:NCT01185262.

 



Results

We reported our completed Phase I/II study, 29pt from 7 Spanish sites were enrolled, 4 of them were screening failures because criteria not fulfilled, and 5 withdrew consent to participate before starting treatment. Median age 75 yr (45-86), male/female 11/9, ECOG 0/1/2: 7/12/1, median time from diagnosis 7.8 yr, median number of previous lines 2 (1-4) all but 2 pt had received fludarabine. In  phase I the MTD of lenalidomide was 15 mg. Effectiveness: In phase II ORR 7 pt (53%), all PR, estimated TTP 15.4 months, estimated OS 21.9 months. Toxicity: 34 SAE were reported, in 6 cases treatment was discontinued definitively (infection 4 pt, progressive multifocal leukoencephalopathy 1pt, amyotrophic lateral sclerosis 1pt). Grade 4 neutropenia was the main adverse event associated with the regimen.



Summary
In our experience 15 mg is the MTD of daily lenalidomide in combination with rituximab every 28 days in R/R CLL patients. The combination was effective and well tolerated with a 53% ORR and 21.9 months estimated OS.

Keyword(s): Chronic lymphocytic leukemia, Phase I/II, Salvage therapy

Session topic: Chronic lymphocytic leukemia - Clinical 1
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings